Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/29/2020 07/30/2020 07/31/2020 08/03/2020 08/04/2020 Date
276.4(c) 273.84(c) 281.34(c) 283.68(c) 282.86(c) Last
843 287 917 880 1 491 504 1 215 314 829 018 Volume
+1.25% -0.93% +2.74% +0.83% -0.29% Change
More quotes
Financials (USD)
Sales 2020 16 995 M - -
Net income 2020 1 233 M - -
Net Debt 2020 15 036 M - -
P/E ratio 2020 72,5x
Yield 2020 1,20%
Sales 2021 18 526 M - -
Net income 2021 2 439 M - -
Net Debt 2021 12 732 M - -
P/E ratio 2021 28,8x
Yield 2021 1,30%
Capitalization 83 674 M 83 674 M -
EV / Sales 2020 5,81x
EV / Sales 2021 5,20x
Nbr of Employees 70 093
Free-Float 79,3%
More Financials
Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (52.4%): surgical instruments (71.6% of net sales), pharmaceutical systems (16.2%), and diabetes care products (12.2%); - diagnostic materials (24.9%): automated systems for blood testing, mycobacteria... 
More about the company
Surperformance© ratings of Becton, Dickinson and Comp
Trading Rating : Investor Rating :
More Ratings
Latest news on BECTON, DICKINSON AND COMP
08/03BECTON, DICKINSON AND COMPANY : quaterly earnings release
08/03BECTON DICKINSON AND : BD releases FY 2019 Sustainability Report
PR
07/31BECTON DICKINSON AND : BD Announces $24 Million U.S. Government Investment to Su..
PU
07/30BECTON DICKINSON AND : BD Announces $24 Million U.S. Government Investment to Su..
PR
07/30BECTON DICKINSON AND : Dickinson Gets US Grant to Scale Up Covid-19 Test Product..
DJ
07/28BECTON DICKINSON AND : BD Launches Next Generation Microbiology Solution for Liq..
PU
07/23BECTON DICKINSON AND : BD receives FDA Approval for HPV Test with Extended Genot..
AQ
07/22BECTON DICKINSON AND : Gets FDA Approval for HPV Test with Extended Genotyping C..
DJ
07/21BECTON DICKINSON AND : Gets Orders for Additional 177 Million Injection Devices
DJ
07/21BECTON DICKINSON AND : BD Receives Additional Orders For 177 Million Injection D..
PR
07/15U.S. government agrees to buy Becton's COVID-19 testing devices
RE
07/15BECTON DICKINSON : HHS to Buy Veritor Plus Systems, SARS-CoV-2 Test Kits
DJ
07/15BECTON DICKINSON AND : BD Supports U.S. Government Efforts to Increase COVID-19 ..
PR
07/08BECTON DICKINSON AND : Beckton Dickinson Partners With U.S. Government to Make I..
DJ
07/08BECTON DICKINSON AND : BD Partners with U.S. Government on $70 Million Manufactu..
PR
More news
News in other languages on BECTON, DICKINSON AND COMP
08/03BECTON, DICKINSON AND COMPANY : quaterly earnings release
08/03BECTON DICKINSON AND : BD releases FY 2019 Sustainability Report
08/03BECTON, DICKINSON AND COMPANY : Veröffentlichung des Quartalsergebnisses
08/03BECTON, DICKINSON AND COMPANY : publication des résultats trimestriels
07/31BECTON DICKINSON AND : BD Announces $24 Million U.S. Government Investment to Su..
More news
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMP
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 280,17 $
Last Close Price 283,43 $
Spread / Highest target 5,85%
Spread / Average Target -1,15%
Spread / Lowest Target -12,5%
EPS Revisions
Managers
NameTitle
Thomas E. Polen President, Chief Executive Officer & Director
Vincent A. Forlenza Executive Chairman
Christopher R. Reidy Chief Financial Officer, CAO & EVP-Administration
John A. DeFord Chief Technology Officer & Executive VP
William R. Sigmund Chief Medical Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
BECTON, DICKINSON AND COMPANY4.00%83 674
ABBOTT LABORATORIES15.05%176 929
MEDTRONIC PLC-15.13%129 154
DEXCOM, INC.102.02%42 308
BAXTER INTERNATIONAL INC.-3.04%41 045
HOYA CORPORATION1.24%36 667